TY - JOUR
T1 - Initiation and use of propranolol for infantile hemangioma
T2 - Report of a consensus conference
AU - Drolet, Beth A.
AU - Frommelt, Peter C.
AU - Chamlin, Sarah L.
AU - Haggstrom, Anita
AU - Bauman, Nancy M.
AU - Chiu, Yvonne E.
AU - Chun, Robert H.
AU - Garzon, Maria C.
AU - Holland, Kristen E.
AU - Liberman, Leonardo
AU - MacLellan-Tobert, Susan
AU - Mancini, Anthony J.
AU - Metry, Denise
AU - Puttgen, Katherine B.
AU - Seefeldt, Marcia
AU - Sidbury, Robert
AU - Ward, Kendra M.
AU - Blei, Francine
AU - Baselga, Eulalia
AU - Cassidy, Laura
AU - Darrow, David H.
AU - Joachim, Shawna
AU - Kwon, Eun Kyung M.
AU - Martin, Kari
AU - Perkins, Jonathan
AU - Siegel, Dawn H.
AU - Boucek, Robert J.
AU - Frieden, Ilona J.
PY - 2013/1
Y1 - 2013/1
N2 - Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.
AB - Infantile hemangiomas (IHs) are common neoplasms composed of proliferating endothelial-like cells. Despite the relative frequency of IH and the potential severity of complications, there are currently no uniform guidelines for treatment. Although propranolol has rapidly been adopted, there is significant uncertainty and divergence of opinion regarding safety monitoring, dose escalation, and its use in PHACE syndrome (PHACE = posterior fossa, hemangioma, arterial lesions, cardiac abnormalities, eye abnormalities; a cutaneous neurovascular syndrome characterized by large, segmental hemangiomas of the head and neck along with congenital anomalies of the brain, heart, eyes and/or chest wall). A consensus conference was held on December 9, 2011. The multidisciplinary team reviewed existing data on the pharmacologic properties of propranolol and all published reports pertaining to the use of propranolol in pediatric patients. Workgroups were assigned specific topics to propose protocols on the following subjects: contraindications, special populations, pretreatment evaluation, dose escalation, and monitoring. Consensus protocols were recorded during the meeting and refined after the meeting. When appropriate, protocol clarifications and revision were made and agreed upon by the group via teleconference. Because of the absence of high-quality clinical research data, evidence-based recommendations are not possible at present. However, the team agreed on a number of recommendations that arose from a review of existing evidence, including when to treat complicated IH; contraindications and pretreatment evaluation protocols; propranolol use in PHACE syndrome; formulation, target dose, and frequency of propranolol; initiation of propranolol in infants; cardiovascular monitoring; ongoing monitoring; and prevention of hypoglycemia. Where there was considerable controversy, the more conservative approach was selected. We acknowledge that the recommendations are conservative in nature and anticipate that they will be revised as more data are made available.
KW - Bradycardia
KW - Hypertension
KW - Hypoglycemia
KW - Infantile hemangioma
KW - PHACE syndrome
KW - Propranolol
UR - http://www.scopus.com/inward/record.url?scp=84872283531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872283531&partnerID=8YFLogxK
U2 - 10.1542/peds.2012-1691
DO - 10.1542/peds.2012-1691
M3 - Article
C2 - 23266923
AN - SCOPUS:84872283531
SN - 0031-4005
VL - 131
SP - 128
EP - 140
JO - Pediatrics
JF - Pediatrics
IS - 1
ER -